Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1A clinical trials to treat immuno-oncology indications. It is also developing NX 0479/GS 6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.

Nurix Therapeutics Inc.

Nurix Therapeutics, Inc. ($NRIX) announced an update on their ongoing clinical study. The phase 3 study “A Phase 3, Randomized, Open-label, Multice...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	NRIX	$15.64	-4.34%	1.12M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	NRIX	$15.64	-4.3%	1.12M
3
4
5
6

NRIX

NRIX

Get Nurix Therapeutics Inc. Data in Excel

Get Nurix Therapeutics Inc. Data in Excel